2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5011 Menin inhibitor exposure creates a therapeutic vulnerability to rigosertib in KMT2Ar acute myeloid leukemia

Jeff Justin Aguilar, MD, MBA, Sandhya Dhiman2, Asmita Shukla, MD3, Vikram Dhillon, DO, MBA4, Dakshin Padmanabhan, MD5, Sikander Chohan, MD6, Anisha Rajavel, DO7, Yang Shi, PhD8, Julie Boerner, PhD9, Jay Yang, MD10, Suresh Kumar Balasubramanian, MD11
1 Karmanos Cancer Institute, Detroit, United States
2 Karmanos Cancer Institute, Detroit, United States
3 Karmanos Cancer Institute, Detroit, United States
4 Karmanos Cancer Institute, Detroit, United States
5 Karmanos Cancer Institute, Detroit, United States
6 Karmanos Cancer Institute, Detroit, United States
7 Karmanos Cancer Institute, Detroit, United States
8 Karmanos Cancer Institute, Detroit, United States
9 Karmanos Cancer Institute, Detroit, United States
10 Karmanos Cancer Institute, Detroit, United States
11 Karmanos Cancer Institute, Detroit, United States

Introduction

Menin inhibitors (MI) modulate the epigenetic landscape in acute myeloid leukemia (AML), creating broader sensitivity in vulnerable dependencies that can also be exploited for rational combination therapies. Identifying ideal synergistic partners for menin inhibition is a priority, as acquired clinical resistance limits their durability of response. Our prior work identified rigosertib, which disrupts MAPK, PI3K/AKT, PLK1, and RAS-effector signalling, as a sensitizer in MI-exposed R/R AML based on an ex vivo drug sensitivity analysis in primary patient samples. We aim to investigate why rigosertib could potentially work in patients treated with a MI.

Methods

We analyzed ex vivo drug-sensitivity and transcriptomic data from R/R AML specimens to identify differentially drug-sensitive samples to 64 anti-cancer drugs. These drugs included kinase, JAK, and MEK inhibitors, epigenetic modulators, HDAC and BET inhibitors, anti-apoptotic pathway drugs, and p53 activators. Other drugs were hypomethylating agents, immunomodulatory drugs, and drugs targeting oncogenic drivers or DNA damage repair. An in vitro MI resistant model in KMT2Ar leukemia cell line (MV4-11) was developed by chronically exposing it to sequentially escalating, subtherapeutic doses of a MI [ziftomenib, Selleckchem, cat. no.: E1290]. We performed rigosertib dose-response studies in parental MV4-11 cells and the MI-resistant MV4-11 model. AKT, MAPK, RAS, and mTOR signalling proteins were evaluated by immunoblotting in parental MV4-11 cells, then in cells exposed to MI for 24, 48, and 72 hours, and MI-resistant cells (as deemed by their increased IC50 at least 5 times above the sensitive cell line). RT-qPCR quantified AKT1, PLK1, and NRAS expression across the same states. Functional dependency was assessed using 100 nM siRNA targeting AKT1, MAPK1, or PLK1 individually or in combination, followed by cell-viability assessment and immunoblotting.

Results

3 primary patient derived relapsed refractory AML samples were identified to have been exposed to MI. 2 of 3 samples (ARF014, ARF016) from patients on treatment with MI were rigosertib-sensitive ex vivo, whereas 1 of 3 was remotely treated with MI for a short duration and was not sensitive to rigosertib. Gene expression (Z-score of FPKM, with log fold-change) was compared between samples across eight curated pathway panels (Cell Cycle/PLK1, RAS/MAPK Signalling, PI3K/AKT/mTOR, Apoptosis, Epigenetic Modifiers, AML Stemness/LSC, FLT3/Receptor Signalling, and Ubiquitin/Proteasome). The sensitive samples showed differential activity across cell-cycle/PLK1, RAS/MAPK, and PI3K/AKT/mTOR programs relative to the other samples. These expression data provide a rationale to interrogate these pathways experimentally. MI-resistant cells were more sensitive to rigosertib than parental MV4-11 cells (IC50 21.5 nM vs 79 nM; approximately 4-fold shift).

Immunoblotting revealed dynamic signalling changes during acute MI exposure and acquired resistance, with persistent MAPK expression and alterations in AKT, RAS, and mTOR. RT-qPCR showed marked PLK1 suppression during acute MI exposure followed by partial restoration in chronically MI exposed cells; NRAS fell during acute exposure and rose in the resistant state, whereas AKT1 exhibited a non-linear pattern and remained detectable in resistant cells.

siRNA-mediated knockdown of AKT1, MAPK1, or PLK1 individually or in combination produced differential, time-dependent effects on MV4-11 cell viability. Single-gene knockdowns reduced viability to varying degrees, and the combined knockdown produced the greatest reduction in cell viability over a 24 h time course. Immunoblotting confirmed target engagement, with reduced AKT1, MAPK1 and PLK1 expression following independently targeting siRNA.

Conclusion

MI exposure in a time-dependent manner generates an escape signalling state that is not dominant without prior MI exposure, creating a novel vulnerable state that could be targeted with small-molecule inhibitors. Rigosterib is a potent multi-kinase inhibitor that could target these signalling mechanisms in MI-exposed patients, justifying its use as a novel sequential synergistic partner. Known evidence supports epigenetic reprogramming in MI-treated states. We are able to show that dynamic kinase signalling pathway modification using rigosertib as a rational combination strategy with a MI.
Jeff Justin Aguilar, MD, MBA: No relevant conflicts of interest to declare.